TRV GP III’s Fulcrum Therapeutics FULC Stock Holding History

TRV GP III’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,962,202	Closed	-$14.3M	–	4
2022 Q4	$14.3M	Sell	1,962,202 -2,000,000	-50%	-$13M	11.2%	4
2022 Q3	$32.1M	Hold	3,962,202	–	–	14%	4
2022 Q2	$19.4M	Hold	3,962,202	–	–	7.94%	5
2022 Q1	$93.7M	Hold	3,962,202	–	–	25.43%	2
2021 Q4	$70.1M	Sell	3,962,202 -1,000,000	-20%	-$19.8M	17.54%	4
2021 Q3	$140M	Sell	4,962,202 -1,000,000	-17%	-$18.9M	26.57%	2
2021 Q2	$62.5M	Hold	5,962,202	–	–	10.91%	4
2021 Q1	$70.2M	Hold	5,962,202	–	–	8.88%	4
2020 Q4	$69.8M	Hold	5,962,202	–	–	6%	5
2020 Q3	$47.3M	Hold	5,962,202	–	–	3.97%	6
2020 Q2	$109M	Hold	5,962,202	–	–	15.92%	3
2020 Q1	$71.2M	Hold	5,962,202	–	–	19.37%	2
2019 Q4	$99.2M	Hold	5,962,202	–	–	43.81%	1
2019 Q3	$39.6M	Buy	+5,962,202	New	+$66M	22.43%	2

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TRV GP III's FULC Position: Q1 2023 in Review

TRV GP III sold out of Fulcrum Therapeutics (FULC) in Q1 2023, closing a stake of 1,962,202 shares — an estimated $14.3M sold.

TRV GP III first reported a position in FULC in Q3 2019 and held it in 14 quarters. The position peaked at $140M in Q3 2021. 116 funds tracked by Wall St. Rank hold FULC as of Q1 2023.

TRV GP III reported no remaining Fulcrum Therapeutics position as of Q1 2023 after selling out during the quarter.
TRV GP III sold 1,962,202 Fulcrum Therapeutics shares in Q1 2023, an estimated $14.3M.
TRV GP III first reported a position in Fulcrum Therapeutics in Q3 2019 and held it in 14 quarters.
TRV GP III's Fulcrum Therapeutics position peaked at $140M in Q3 2021.
116 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2023.

Based on TRV GP III's 13F filing for Q1 2023, filed 12 May 2023.